← All trials
NCT05853341
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2023
- Primary completion
- Jul 2, 2023
- Completion date
- Jul 17, 2023
- First posted
- May 10, 2023
- Last posted
- Oct 19, 2023
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Luye PharmaLead sponsor
- SocraTec R&D GmbHCollaborator
- SocraTec R&D GmbHOverall official - principal investigator
- SocraMetrics GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.